Recent research into the use of daridorexant used change from baseline in wake after sleep onset and latency to persistent sleep (LPS) at months 1 and 3 as its primary endpoints. Secondary endpoints included change in the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) sleepiness domain score and change from baseline in self-reported total sleep time (TST) at months 1 and 3.
A 50-mg dose of daridorexant was linked to a reduction in LPS of 11.7 min at month 3 vs placebo. Compared with placebo, the 25-mg dose was associated with significant reductions in wake after sleep onset at month 1 (11.6 min, P = .0001) and month 3 (10.3 min, P = .0028) compared with placebo. However, the 25-mg dose was not associated with significant differences in LPS at either timepoint. Similarly, the 25-mg dose was linked to improvements in self-reported TST but not to improved IDSIQ sleepiness score. The 10-mg dose was not associated with improvements at any endpoint compared with placebo.
Learn more about daridorexant.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Stephen Soreff, Helmi L. Lutsep. Rapid Review Quiz: Insomnia Recent Studies - Medscape - Feb 14, 2022.